SEC Form 4 · accession 0001181431-15-005320
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Cannell
Officer — Chief Commercial Officer
Period of report
Mar 30, 2015
Accepted (ET)
Mar 31, 2015 · 7:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $7.75 | Mar 30, 2015 | A | 425,000 | A | — | Mar 29, 2025 | Common Stock | 425,000 | 425,000 | D |
Explanation of responses
- F125% of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on 3/30/2016 and 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month thereafter, so that all of the shares of stock subject to the option shall be vested on 3/30/2019, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary of the Issuer on each such date.
- F2Not Applicable